Top News

Sorrento Therapeutics To Buy IGDRASOL




San Diego-based biopharmaceuticals developer Sorrento Therapeutics announced today that it has signed an exclusive option to acquired Fountain Valley-based IGDRASOL, a company developing oncologic agents for treating metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC) and other cancers. Sorrento said it will buy IGDRASOL by issuing 76,199,171 shares of its common stock, or approximately $18.2M. The firm also said it will pay out an additional 32,656,788 shares of its common stock if regulatory milestones are met.


 

Marketplace


 

 

Latest Headlines

Browse Issues

 
 

Keep up with all of the latest Southern California high tech news via email (it's free!)



or Cancel